Medtronic issues recall diabetes software affecting CareLink version 4.2B due to incorrect glucose data display, prompting clinician review.

Medtronic has reported 6.6% revenue growth to $9B in Q2 2026, led by its cardiovascular portfolio's 10.8% increase and 71% ...

Medtronic's diabetes business was a sweet spot in the company's fiscal first quarter of 2024. After FDA approved the company's MiniMed 780G system with the Guardian 4 sensor in April, analysts and ...

Danish diabetes-tech company Hedia has announced the appointment of Rasmus Kofoed as its new CEO.

Medtronic has announced plans to separate out its diabetes business into a new standalone company. The separation will serve to create an “independent, scaled leader in diabetes” that boasts an ...

Medtronic announced Wednesday that it will spin off its diabetes business into a standalone company. The medical device giant, which is domiciled in Dublin, Ireland but has its main office in Fridley, ...

While insulin pumps and continuous glucose monitors have improved the lives of many Type 1 diabetes patients, some still ...

Medtronic leaders Geoff Martha, Thierry Piéton and Laura Mauri offer their thoughts on M&A, R&D, RDN, PFA, Hugo and other ...

The U.S. Food and Drug Administration says Medtronic's diabetes business is back in compliance. The agency issued a warning letter in December 2021 that detailed concerns about how Medtronic handled ...

Health tech company Medtronic is acquiring insulin patch pump company EOFlow for $738 million, the company announced Thursday. The acquisition is meant to bolster Medtronic’s diabetes offerings and ...

In just the last few years, diabetes technology has grown exponentially smarter. Top of mind now for many devicemakers is the creation of a truly closed-loop system for insulin delivery—a system often ...

Medtronic is the world’s largest pure-play medical device company. It is a dividend aristocrat, conservatively financed and well diversified. It seems like a great long-term investment. The company ...